AlphaLiquidⓇ100 is a liquid biopsy test designed for patients with advanced solid cancers. Our patented UniqSeqⓇ technology detects minuscule amount of ctNDA (circulating tumor NDA) in the bloodstream for comprehensive genomic analysis.
AlphaLiquidⓇ100 detects the four classes of variations (SNV, INDEL, fusion, and CNV) in 106 NCCN-recommended genes associated with major cancer types. With this data, IMB Dx can provide information on appropriate therapy options and related on-going clinical trials.
106 Gene List
Includes genes related to solid tumors recommended by NCCN. Tested for the four mutations (SNVs, INDEL, fusion, CNVs) and MSI.
ABL1 |
AKT1 |
AKT2 |
ALK* |
APC |
AR |
ARAF |
ARID1A |
ATM |
BCR** |
BRAF* |
BRCA1 |
BRCA2 |
BTK |
CBL |
CCND1 |
CCND2 |
CCNE1 |
CD274 |
CDH1 |
CDK4 |
CDK6 |
CDKN2A |
CEBPA |
CSF1R |
CTNNB1 |
DDR2 |
DPYD |
EGFR |
ERBB2 |
CDK4 |
CDK6 |
CDKN2A |
CEBPA |
CSF1R |
CTNNB1 |
DDR2 |
DPYD |
EGFR |
ERBB2 |
ERBB3 |
ESR1 |
FBXW7 |
FGFR1 |
FGFR2* |
FGFR3* |
FLT3 |
GATA3 |
GNA11 |
GNAQ |
GNAS |
HRAS |
IDH1 |
IDH2 |
IGF1R |
JAK2 |
JAK3 |
KDM6A |
KDR |
KEAP1 |
GNAS |
HRAS |
IDH1 |
IDH2 |
IGF1R |
JAK2 |
JAK3 |
KDM6A |
KDR |
KEAP1 |
KIT |
KRAS |
MAP2K1 |
MAP2K2 |
MAPL1 |
MAPK3 |
MDM2 |
MET |
MLH1 |
MPL |
MSH2 |
MSH6 |
MTOR |
MYC |
MYCN |
NF1 |
NF2 |
NFE2L2 |
NOTCH1 |
NPM1 |
NRAS |
NTRK1* |
NTRK2* |
NTRK3 |
PDCD1LG2 |
PDGFRA |
PDGFRB |
PIK3CA |
PIK3R1 |
PMS2 |
PPP2R1A |
PTEN |
PTPN11 |
RAF1 |
RB1 |
RET* |
RHEB |
RHOA |
RIT1 |
RNF43 |
ROS1* |
RUNX1 |
SETD2 |
SMAD4 |
SMO |
STAG2 |
STK11 |
TCF7L2 |
TERT*** |
TOP2A |
TP53 |
TSC1 |
TSC2 |
U2AF1 |
UGT1A1 |
VHL |
|
|
|
|